Tue, Jul 29, 2014, 1:43 AM EDT - U.S. Markets open in 7 hrs 47 mins

Recent

% | $
Click the to save as a favorite.

Celldex Therapeutics, Inc. Message Board

  • mymandon mymandon Aug 9, 2013 12:43 PM Flag

    Gentlemen. Get in Merrimack (MACK) today.

    I've been watching and waiting on this fledgling biotech for almost a year. I knew they needed to raise capital and a dilutino was coming. Now that the secondary is done and post dilution malaise has take price down to $4. I'm all in at $4.02 yesterday . Nice set of catalysts coming in 4Q (phase III top-line results on 398 and host of phase II data). This one will not stay under $5 for long. Come join me at MACK for some fresh new spec biotech action. Don't get me wrong I'm still long Celldex, but MACK is nice little company that's still largely under the Wall Street radar (ala Celldex 18 months ago)!

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Mymandon,

      Why do you think MACK's 398 will work in pancreatic? Pancreatic has been a graveyard for small-cap bio drug development (see GNVC). If 398 fails, THEN there will be a great buying opportunity.

      Bladerunner

      Sentiment: Strong Buy

    • Don, I'm with you on that one! Got in at 4.05...But I think at 7 will get out...This is not CLDX...Not yet.
      And waiting to get in CCXI at 11.3-11.6 it is getting there but slowly...

      • 1 Reply to kot882001
      • Agree MACK is not Celldex, but the science and platform have excellent upside potential and have been suffciently beat up by Wall Street to make them seriously undervalued- similar to where Celldex was a few years back . MACK is still a speculative biotech (until the early 398 data is secured), but once it is (within next 4-5 months), then people will start to take notice. They still need to jump some hoops but at nadir prcing there is money to be made going forward in all likelihood. I don't really see Celldex as truely speculative anymore because Wall Street has recognized the value proposition. MACK is under the radar, but like Celldex has good things cooking that when served up in the nottoo distant future should be delightful for stakeholders, indeed.

        Sentiment: Strong Buy

 
CLDX
13.09-0.48(-3.54%)Jul 28 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.